Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Freedom Finance and Binance Join Forces in Digital Assets 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
GAITHERSBURG, Md., May 02, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018.
Conference call details are as follows:
| Date: | May 9, 2018 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 9, 2018 until | |
| 7:30 p.m. ET May 16, 2018 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until August 9, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com.
Contact:
Investors
Erika Trahan
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
